By: IPP Bureau
Last updated : November 01, 2021 10:34 am
The Akovaz brand and generic market had U.S. sales of approximately US $ 67.5 million MAT for the most recent twelve months ending in August 2021
Dr. Reddy’s announced the launch of Ephedrine Sulfate Injection USP, 50 mg/mL, a therapeutic equivalent generic version of Akovaz (ephedrine sulfate injection) Injection, 50 mg/mL approved by the U.S. Food and Drug Administration (USFDA). The Akovaz brand and generic market had U.S. sales of approximately US $ 67.5 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health.
Dr. Reddy’s Ephedrine Sulfate Injection USP, 50 mg/mL is a clear, colourless, sterile solution for intravenous injection and supplied as a 1 mL fill in a 2 mL clear glass single-dose vial with purple flip-off cap. Each mL contains 50 mg of ephedrine sulfate USP, equivalent to 38 mg ephedrine base.